Daniels 2008.

Methods	Allocation concealment unclear, computer‐generated randomisation sequences, double‐blind, cross‐over design 124/144 analysed
Participants	Included: women with primary dysmenorrhoea, healthy, non‐lactating,  pregnancy test negative, using birth control Excluded: women with secondary dysmenorrhoea, hypersensitivity to NSAIDs, bowel disease or ulcers
Interventions	Naproxen 500 mg Placebo Medicate twice daily
Outcomes	Change in pain intensity (SPID score) Adverse effects
Notes	Study also included lumiracoxib (since withdrawn)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated
Allocation concealment (selection bias)	Unclear risk	Method not described
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double‐blinded, placebo not described
Selective reporting (reporting bias)	Unclear risk	"Adverse events were recorded throughout the study"
Complete follow‐up?	High risk	124/144 analysed (86%)
Potential bias related to study funding	High risk	Novartis sponsored